Introduction: Ocular toxocarosis associated with high peripheral eosinophilia and together with systemic signs of visceral damage has been reported sporadically. Eye infections caused by numerous migrating larvae of Toxocara parasites, probably due to re-invasion or delayed reactivation, and leading to a progressive loss of vision is relatively rare. We report three atypical cases of toxocarosis with the co-existence of ocular larva migrans syndrome and generalized signs of Toxocara infection in schoolboys.

PurposeThe aim of this study was to report on results of uveal melanoma treatment with ruthenium-106 (106Ru) brachytherapy with long-term follow-up, in terms of local tumor control, eye retention rate, radiation retinopathy, and patients’ survival.Material and methodsMedical records of patients treated with ruthenium plaque due to uveal melanoma at the Department of Ophthalmology, Poznan University of Medical Sciences, Poland, between 1994 and 2014 were retrospectively reviewed.ResultsWe identified 126 patients: 53 men, 73 women, mean age 60.04 years (range, 21-89). The largest basal diameter ranged from 4.04 mm to 18.9 mm (median, 10.67 mm), tumor height was 1.9 mm to 7.42 mm (median, 4.8 mm). Median scleral radiation dose was 570 Gy (range, 235-1,500 Gy), median apical dose 100 Gy (range, 60-129 Gy). Median follow-up was 66.5 months (range, 2-261 months). We noted a total of 19 (15%) recurrences. The actuarial rate of recurrence was 9.5% at 3 years, and 13.5% at 5 years postoperatively. Nine (7%) eye globes were lost, median time to enucleation was 5 years. The eye retention rate at 5 years was 92.7% and 81% at 10 years. Forty-three (34%) patients died before the end of the study, 24 (19%) of them due to metastatic disease. Metastatic death was related to: tumor size and TNM stage at presentation (p = 0.002 vs. p = 0.0006, respectively) but not to age, gender, and plaque dosimetry.Conclusions 106Ru brachytherapy is an effective, globe sparing treatment that provides good tumor control and a high rate of survival. However, some ocular complications tend to appear late post-treatment, and therefore long-term follow-up is advised.

PurposeLiverpool Uveal Melanoma Prognosticator Online (LUMPO) is a tool developed by Eleuteri et al. to establish the prognosis for uveal melanoma patients according to the initial tumour characteristics and cytogenetic data. It has been validated with two separate cohorts of patients in United Kingdom and more recently in US. The aim of this study was to test the prognosticator in a homogenous group of patients treated with with ruthenium brachytherapy where genetic analysis was not performed.MethodsThe records of the patients treated with ruthenium brachytherapy for uveal melanoma at the Department of Ophthalmology, Poznan University of Medical Sciences between 1994 and 2012 were retrospectively reviewed. The probability of 3‐year, 5‐year and 10‐year metastasis free survival were obtained for each patient using the LUMPO accessed online and then compared with the existing follow‐up data.ResultsWe identified 102 patients, 60 women, 42 men in a mean age of 59 years. Mean largest basal diameter of the treated tumours was 9.29 (range: 4.04–18.9 )mm, mean tumour thickness: 4.8 (range: 2.6–7.01) mm. Follow‐up ranged from 3 to 22 years, mean: 7.55 years. 33 patients died, 18 (17.65%) out of metastatic disease. The metastatic death was not related to patients’ age (p = 0.6866), LBD (p = 0.3049) or tumour thickness (p = 0.7063) alone. The probability of metastasis free survival according to LUMPO was significantly lower for the metastatic group comparing to the surviving group at 3 years (p = 0.0017) and 5 years post treatment (p = 0.0001).ConclusionsLUMPO is a useful tool for prognostication for uveal melanoma patients. However, the use of cytogenetic data makes this prognosis more precise.

PurposeLiverpool Uveal Melanoma Prognosticator Online (LUMPO) is a tool developed by Eleuteri et al. to establish the prognosis for uveal melanoma patients according to the initial tumour characteristics and cytogenetic data. It has been validated with two separate cohorts of patients in United Kingdom and more recently in US. The aim of this study was to test the prognosticator in a homogenous group of patients treated with ruthenium brachytherapy where genetic analysis was not performed.Material and methodsThe records of the patients treated with ruthenium brachytherapy for uveal melanoma at the Department of Ophthalmology, Poznan University of Medical Sciences between 1994 and 2012 were retrospectively reviewed. The probability of 3‐, 5‐ and 10‐year metastasis free survival were obtained for each patient using the LUMPO accessed online and then compared with the existing follow‐up data.ResultsWe identified 102 patients, 60 women, 42 men in a mean age of 59 years. Mean largest basal diameter of the treated tumours was 9.29 (range: 4.04–18.9) mm, mean tumour thickness: 4.8 (range: 2.6–7.01) mm. Follow‐up ranged from 3 to 22 years, mean: 7.55 years. 33 patients died, 18 (17.65%) out of metastatic disease. The metastatic death was not related to patients’ age (p = 0.6866), LBD (p = 0.3049) or tumour thickness (p = 0.7063) alone. The probability of metastasis free survival according to LUMPO was significantly lower for the metastatic group comparing to the surviving group at 3 years (p = 0.0017) and 5 years post treatment (p = 0.0001).ConclusionsLUMPO is a useful tool for prognostication for uveal melanoma patients. However, the use of cytogenetic data makes this prognosis more precise.

No abstract